Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)
This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, investigators aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the well-documented immune-tolerant tumor microenvironment of liver metastases and their role in systemic resistance to checkpoint inhibitors, investigators hypothesize that histotripsy-induced tumor disruption will lead to measurable alterations in peripheral T-cell clonal expansion and exhaustion markers. Investigators will assess these changes via serial blood draws before and after histotripsy, with the goal of characterizing the systemic immune impact of local tumor ablation. Findings from this study may inform future combination strategies integrating histotripsy with immunotherapy to enhance treatment response in microsatellite-stable CRC
• Gender: Both male and female patients will be eligible for enrollment.
‣ Age at least 18 years.
⁃ Histologic (biopsy-proven) confirmation of metastatic microsatellite stable colorectal cancer with at least one radiographically evident hepatic metastasis.
⁃ Planned treatment with standard-of-care histotripsy.
⁃ Radiographic confirmation of hepatic metastases with computed tomography (CT) or magnetic resonance imaging (MRI), with CT preferred. Imaging must be performed within 60 days of the date of consent.
⁃ Adequate organ and marrow function as defined below:
• Absolute neutrophil count: ≥ 1,000/mcL
∙ Platelets: ≥ 100,000/mcL
∙ Total bilirubin ≤ 3x the upper limit of normal (ULN). This may be up to 5x ULN if Gilbert's syndrome is documented.
∙ AST and ALT ≤ 8x institutional ULN.
∙ Serum creatinine ≤ 2x ULN unless on dialysis.
⁃ Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3.
⁃ Estimated life expectancy of at least 90 days as determined by the treating physician.
⁃ Demographic group: There are no restrictions based on race or ethnicity. Efforts will be made to ensure a representative patient population reflecting the diversity of individuals affected by CRCLM.
⁃ Ability to understand and willingness to sign a written informed consent document.